Home › Funds › SOMERVILLE KURT F › VRTX

SOMERVILLE KURT F position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

SOMERVILLE KURT F reported holding 14,261 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$7.5M, representing 2.12% of its reported portfolio and ranking #20 among its reported holdings. SOMERVILLE KURT F has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)14.26K sh
Reported value held$7.46M
Portfolio Weight2.12%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SOMERVILLE KURT F's VRTX position evolved

SOMERVILLE KURT F first disclosed a stake in VRTX in Q3 2023 at 1,425 shares (US$496K). The position peaked in Q1 2025 at 22,876 shares, worth US$11.1M. Across 13 filings, SOMERVILLE KURT F increased the stake 8 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 14,261 shares valued at US$7.5M — a reduction of -2,180 shares quarter over quarter.. Notable position changes include a 53% increase in Q4 2023 (shares rose 2% over the following quarter), a 121% increase in Q1 2024 (shares rose 12% over the following quarter), a 152% increase in Q2 2024 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.43K $495.53K New
Q4 2023 2.17K $884.99K Add
Q1 2024 4.80K $2.01M Add
Q2 2024 12.10K $5.67M Add
Q3 2024 16.64K $7.74M Add
Q4 2024 20.39K $8.21M Add
Q1 2025 22.88K $11.09M Add
Q2 2025 23.19K $10.32M Add
Q3 2025 22.64K $8.87M Reduce
Q4 2025 23.33K $10.58M Add
Q1 2026 16.73K $7.47M Reduce
Q2 2026 16.44K $8.17M Reduce
Q3 2026 14.26K $7.46M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has SOMERVILLE KURT F held VRTX?

SOMERVILLE KURT F has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is SOMERVILLE KURT F's current position in VRTX?

As of Q3 2026, SOMERVILLE KURT F holds 14.26K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $7.46M, representing 2.12% of its reported portfolio and ranking #20.

Has SOMERVILLE KURT F been buying or selling VRTX?

In the latest 13F filing (Q3 2026), SOMERVILLE KURT F reduced its position in VRTX. The position peaked in Q1 2025 at 22.88K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.